Want to see FR:ALIMP full AI Analyst Report?
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.15 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)68.36K
Market Cap
€24.45M
Enterprise Value€28.61
Total Cash (Recent Filing)€1.01M
Total Debt (Recent Filing)€5.46M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Mar 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume46,175
30 Day Avg. Volume68,356
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundRevenue has increased substantially over the reported period, indicating stronger demand for the company’s orthopedic and spine products. If maintained, this expanding top line can improve operating leverage, support broader market adoption, and provide a larger base from which to pursue eventual profitability.
Improving Gross MarginThe meaningful gross-margin improvement suggests that a greater share of product revenue is being retained after direct costs. Sustaining this progress would strengthen the economics of the implant portfolio, increase the potential for operating leverage, and help offset the company’s continuing overhead burden.
Cash Flow Trend ImprovingAlthough operating cash flow remains negative, the sharp year-over-year improvement shows reduced cash consumption from operations. Continued progress could lessen reliance on external funding and move the company closer to self-financing, provided revenue growth and margin gains persist.
Bears Say
Persistent UnprofitabilityThe company has not yet converted its revenue rebound and gross-margin gains into sustainable earnings. Persistent operating and net losses can consume capital, limit financial flexibility, and make future growth dependent on continued funding until the cost base is brought into balance.
Highly Leveraged Balance SheetVery high debt relative to the thin equity base leaves limited protection against further losses or operating setbacks. The prior swing to negative equity highlights the balance-sheet stress, while substantial leverage can constrain capital allocation and increase dependence on successful execution.
Negative Free Cash FlowFree cash flow has remained negative across the reported years, so the business is not yet generating enough cash internally to fund its needs. This ongoing shortfall reinforces reliance on external financing and could limit the company’s ability to invest while losses persist.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.15 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €24.45M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Mar 09, 2027 which is in 169 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Sep 15, 2026. The company reported -€0.015 earnings per share for the quarter.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went down -0.581%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Affluent Medical SA
―